Common questions about Senshio (FAQ)
Q: Is vaginal discharge a common change when starting Senshio?
According to official product information, vaginal discharge or vaginal hemorrhage (bleeding) is listed as a common adverse reaction. This means it was among the effects most frequently reported in clinical trials. It is described as a possible change that may occur when starting the medication.
Q: Can Senshio cause headaches or muscle spasms?
Official regulatory product information confirms that both headache and muscle spasms are listed as common adverse reactions. These were among the side effects most frequently reported by patients in clinical studies for this medicine.
Q: Are there specific antifungal drugs that interact with Senshio?
Regulatory documents note specific interactions involving certain antifungal drugs. Fluconazole, an oral medicine sometimes used for fungal infections, is specifically mentioned because it can potentially increase the amount of Senshio's active substance in the bloodstream.
Q: What happens if I take Senshio with another SERM medication?
The co-administration of Senshio with other Estrogen Agonist/Antagonists, such as other Selective Estrogen Receptor Modulators (SERMs), is prohibited. This restriction is included in regulatory documents due to safety concerns regarding the combination of these treatments.
Q: Are there any known food interactions with Senshio tablets?
Official guidelines state that Senshio should be taken with food to ensure proper absorption of the medicine. However, regulatory documents do not specify any restrictions or other interactions involving specific types of food.
Q: Is Senshio appropriate for women who still have a uterus?
Official information indicates that Senshio can be used by women who have an intact uterus. Official product information discusses the potential risks, such as endometrial thickening, for this patient population. For women with a uterus using Senshio, clinical surveillance is recommended as part of their care.
Q: How long does it typically take to see improvement in vaginal dryness with Senshio?
Clinical efficacy for symptoms like painful intercourse (dyspareunia) and vaginal dryness was evaluated in trials over a 12-week period. This 12-week timeframe is the duration over which the medicine’s effectiveness was formally evaluated in clinical studies.
Q: How does Senshio affect the lining of the uterus (endometrium)?
The active substance in Senshio acts as an estrogen agonist (an activator) on the endometrium, which is the lining of the uterus. This action can lead to an increase in endometrial thickness. Official warnings state that any unexplained bleeding should be investigated.
Q: Is it normal to experience mild vaginal bleeding after starting Senshio?
While vaginal bleeding or hemorrhage is listed as a common adverse reaction, official documents maintain a strict warning about this symptom. Official documents state that any unexplained, persistent, or recurring bleeding should be investigated by a healthcare professional.
Q: Is Senshio only for women who are fully postmenopausal?
Senshio is exclusively indicated for use in women who are postmenopausal. It is not intended for use in premenopausal women or those of childbearing potential, as per regulatory guidelines.
Q: Can Senshio be used by women who have had a hysterectomy?
Senshio can be used by women who have had a hysterectomy (removal of the uterus). The main safety concern discussed in official warnings relates to the effect on the lining of the uterus, which is no longer present after this procedure.
Q: Does Senshio affect fertility?
Senshio is contraindicated in women who are pregnant, breastfeeding, or who may become pregnant. This is because animal studies suggest reproductive effects consistent with its estrogen-receptor activity.
Q: What is the usual length of time Senshio is prescribed for?
Official guidelines recommend using the medicine for the shortest duration consistent with treatment goals. The need for continued treatment should be periodically re-evaluated by a healthcare professional.
Q: How often does a doctor need to review my use of Senshio?
A careful appraisal of the risks and benefits of continued use should be undertaken by a healthcare professional at least annually. This regular review is necessary to ensure the treatment remains appropriate for the patient’s condition.
Q: Does the efficacy of Senshio decrease after long-term use?
Clinical data on the effectiveness of the medicine beyond 12 months of use are limited. This means that long-term studies confirming sustained efficacy past one year are restricted.
Q: Where did Senshio first receive regulatory approval? (e.g., FDA, EMA)
The first regulatory approval for the active substance, ospemifene, was granted by the U.S. Food and Drug Administration (FDA). This approval occurred in February 2013.
Q: Does Senshio contain lactose or other common allergens?
Official product information confirms that Senshio tablets contain lactose. This is an important note for patients who have rare hereditary problems of galactose intolerance.
Q: Is Senshio known to cause urinary tract infections (UTIs)?
Official trial data noted a small increase in the incidence of urinary tract infections compared to placebo. This finding was observed during the clinical studies for the medicine.
Q: Is Senshio considered a preventative treatment or a symptomatic one?
Senshio is indicated for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy. It is used to address the active symptoms of the condition rather than for prevention.
Q: Does Senshio have any impact on the ability to drive or use machinery?
Official product information states that Senshio has no known or very little influence on the ability to drive or use machines. No common side effects listed include impairment of mental or motor function.
